| Name | Title | Contact Details |
|---|
The Vault Health platform provides a robust and flexible technology stack at the foundation of a multimodal healthcare service ecosystem. The platform features a powerful suite of digital healthcare tools designed to tackle a broad scope of modern medical use cases, including individual care, population health, and clinical trials. The Vault digital healthcare toolkit includes on-demand telehealth consultations and sample supervision, patient and provider communications, in-person and remote appointment management, longitudinal care management, and beyond. Vault gravitates to opportunities and partnerships that empower them to share and expand their platform`s capabilities and impact.
ALSM is a not-for-profit organization that has been serving families for 60 years. Our services and programs now span eight counties including Bedford, Blair, Cambria, Centre, Clearfield, Fulton, Huntingdon, and Somerset. ALSM currently offers care at
Pointe Scientific is a Canton, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Founded in 2019, Zing Health Holdings Inc. is a groundbreaking tech-enabled insurance company making Medicare Advantage the best it can be for those 65 and over or with long-term disability. Zing Health`s community-based approach addresses social determinants of health to keep individuals and communities healthy and returns the physician and the member to the center of the healthcare equation. This gives each member personalized care and service tailored to their singular needs. Members also receive individualized assistance to make their transition to Zing Health as easy as possible, and have the ability to personalize their plans, access to facilities designed to help them better meet their healthcare needs, and a dedicated care team.
SCYNEXIS, Inc. is a pharmaceutical company committed to the discovery, development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. Our scientists have extensive experience in the life sciences industry having, together and individually, been involved in the discovery and development of innovative medicines over a broad range of therapy areas. We are developing our lead product candidate, SCY-078, a novel antifungal in Phase 2, as a novel oral and intravenous drug for the treatment of serious and life-threatening invasive fungal infections in humans.